CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
References:
[1]. Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel). 2022 Feb 22;14(5):1113.
[2]. Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.